IMPROVEd Timing On Vytorin Outcomes Data?
This article was originally published in The Pink Sheet Daily
Executive Summary
Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.